Vaccine developer Medicago (TSX:MDG) will target rotavirus, the leading cause of diarrhea in infants and children worldwide, under a new partnership with Japanese firm Mitsubishi Tanabe Pharma. Medicago stands to gain nearly $33 million in payments from Mitsubishi Tanabe under the vaccine collaboration and development deal, plus royalties on future sales of a new rotavirus […]
Vaccine maker Medicago (TSX:MDG) has developed a technology that can turn tobacco leaves into vaccines quickly and inexpensively, and the biotechnology company’s new North Carolina site stands ready for influenza vaccine production. But when Medicago unveiled its new Research Triangle Park facility last November amid great fanfare, CEO Andrew Sheldon said he couldn’t disclose Medicago’s […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biotechnology company Medicago (TSX:MDG), whose technology makes vaccines from tobacco leaves, now has an additional $11.1 million from an investor who knows a thing or two about the golden leaf: Philip Morris (NYSE:PM). Medicago shareholders approved the investment, the second tranche of a $22.5 million private placement with the tobacco giant. Philip Morris is acquiring […]
Biotechnology company Medicago (TSX:MDG) could soon demonstrate whether its technology can rapidly develop and manufacture vaccines to respond to potential pandemic and bioterror threats. Medicago, which is part of a national project to develop vaccine capabilities to respond to virus threats, has launched operations in its Research Triangle Park, North Carolina facility. The company expects […]